Fasting News and Research

RSS

Tonix to initiate TNX-102 PK and BA study for fibromyalgia

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system, including fibromyalgia syndrome and post-traumatic stress disorder, will initiate a comparative pharmacokinetic and bioavailability study of TNX-102, a novel dosage oral formulation of cyclobenzaprine for the treatment of FM, following the U.S. Food and Drug Administration clearance of the Company's initial Investigational New Drug Application.

18 Nov 2011

Vitamin D and its good and bad effects on the heart

Vitamin D in excess may not be beneficial and may even harm the heart says a new study. Scientists have long known that low levels of the nutrient can hurt the heart, but new research shows that higher than normal levels can make it beat too fast and out of rhythm, a condition called atrial fibrillation. The study was presented at the annual meeting of the American Heart Association.

17 Nov 2011

Psoriasis may alter cholesterol composition and decrease HDL function

Collaborative research from Perelman School of Medicine at the University of Pennsylvania has shown that psoriasis patients have an increased risk of heart attack, stroke and cardiovascular death, especially if the psoriasis is moderate to severe. Now, Penn researchers have discovered the potential underlying mechanism by which the inflammatory skin disease impacts cardiovascular health.

17 Nov 2011

Mediterranean diet can reduce risk of future heart disease

A team of Johns Hopkins researchers has uncovered further evidence of the benefits of a balanced diet that replaces white bread and pasta carbohydrates with unsaturated fat from avocados, olive oil and nuts — foods typical of the so-called "Mediterranean diet."

17 Nov 2011

Sugary drinks raise risk of heart disease in women: Study

A new study shows that women who take sugared beverages every day may be raising their risk for heart disease, even if their habit is not packing on the pounds. The researchers say the drinks could be anything - sweet tea, soda, or coffee drinks that look like desserts.

14 Nov 2011

Link between sugar-sweetened beverages and increased cardiovascular risk in women

Drinking two or more sugar-sweetened beverages a day may expand a woman's waistline and increase her risk of heart disease and diabetes, according to research presented at the American Heart Association's Scientific Sessions 2011.

14 Nov 2011

Python heart holds surprises that could be of use in cardiology

The expanding hearts of pythons have intrigued researchers. Leslie Leinwand - a University of Colorado at Boulder molecular biologist who studies heart disease in humans called pythons’ expanding hearts “amazing biology”. “They're not swelling up. They're building (heart) muscle,” he said.

30 Oct 2011

Potential avenue to make an unhealthy heart grow more like a healthy version

Identification of three fatty acids involved in the extreme growth of Burmese pythons' hearts following large meals could prove beneficial in treating diseased human hearts, according to research co-authored by a University of Alabama scientist and publishing in the Oct. 28 issue of Science.

28 Oct 2011

Dietary intervention in adolescence benefits glycemic control and blood pressure long-term

A recent study has found that a childhood behavioral intervention to lower dietary intake of total fat and saturated fat and increase consumption of foods that are good sources of dietary fiber resulted in significantly lower fasting plasma glucose levels and lower systolic blood pressure when study participants were re-evaluated in young adulthood.

28 Oct 2011

Study links leptin levels with symptoms of depression, anxiety

A new study has for the first time in humans linked levels of leptin, a hormone produced by fat cells, with symptoms of depression and anxiety independent of weight.

21 Oct 2011

Takeda commences TAK-875 Phase 3 clinical trial program for type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiaries, Takeda Global Research & Development Center, Inc., and Takeda Global Research & Development Centre (Europe), Ltd., announced today the initiation of the Company's Phase 3 clinical trial program for TAK-875, an investigational therapy for type 2 diabetes.

18 Oct 2011

Scientists discover rare genetic alteration responsible for hypoglycaemia

Cambridge scientists have identified the cause of a rare, life-threatening form of hypoglycaemia. Their findings, which have the potential to lead to pharmaceutical treatments for the disorder, were published today, 07 October, in the journal Science.

7 Oct 2011

FOX06 protein contributes to liver overproduction of glucose in diabetes

Researchers at the John G. Rangos Sr. Research Center at Children's Hospital of Pittsburgh of UPMC and the University of Pittsburgh School of Medicine have identified a powerful molecular pathway that regulates the liver's management of insulin and new glucose production, which could lead to new therapies for diabetes.

29 Sep 2011

The obese can’t help but eat: Study

A new study suggests that brains of people who are obese may be wired differently for impulse control, such as resisting a doughnut when their blood sugar levels drop, compared with people who are not obese.

20 Sep 2011

Regulatory bias against taking oral anti-cancer medications with food places patients at risk of overdose

A regulatory bias against taking oral anti-cancer medications with food places many patients at increased risk for an overdose and forces them to "flush costly medicines down the toilet," argues Mark Ratain, MD, an authority on cancer-drug dosing.

20 Sep 2011

Multiple abstracts on QNEXA presented at 47th EASD

VIVUS, Inc. today announced that multiple abstracts were presented at the 47th European Association for the Study of Diabetes (EASD) Annual Meeting in Lisbon, Portugal. The presentations highlighted the long-term beneficial effects of QNEXA treatment in metabolically-impaired patients with prediabetes, diabetes, and metabolic syndrome.

17 Sep 2011

Novo Nordisk's insulin degludec reduces blood sugar in patients with type 2 diabetes

Ultra-long-acting insulin degludec, an investigational basal insulin being developed by Novo Nordisk, showed significant blood sugar reductions in patients with type 2 diabetes.

From Novo Nordisk 15 Sep 2011

Enrollment commences in ConjuChem's CJC-1134-PC Phase 2 trial for Type 2 diabetes

ConjuChem, LLC, a biotechnology company dedicated to the discovery of novel therapeutics, today announced it has initiated patient enrollment for its Phase 2 clinical trial of its proprietary GLP-1 receptor agonist drug, CJC-1134-PC, in patients with Type 2 diabetes mellitus who are receiving metformin monotherapy.

15 Sep 2011

Nature journal publishes Metabolon's genome wide association study

Metabolon, Inc., the leader in metabolomics, biomarker discovery and biochemical analysis, announced the publication of "Human Metabolic Individuality in Biomedical and Pharmaceutical Research" in the journal Nature.

3 Sep 2011

New guidelines for the treatment of acromegaly, a serious growth hormone disorder

It’s said a lot can happen in seven days. In seven years, a lot has happened in the understanding of acromegaly, a debilitating condition that causes a patient to have too much growth hormone. It’s seven years since the American Association of Clinical Endocrinologists last produced guidelines for the diagnosis and treatment of acromegaly. Their 2004 guidelines were just 13 pages long. Their latest, the 2011 guidelines, have grown – to 44 pages.

31 Aug 2011